Transforming Oncology Prior Authorization Workflows with Experian Health Clearinghouse

The Unique Demands of Oncology Prior Authorization within the Experian Health Clearinghouse Ecosystem

Oncology prior authorization is inherently complex, marked by high-cost treatments, rapid regimen changes, and stringent documentation requirements. While Experian Health Clearinghouse excels at streamlining claims submission and revenue cycle management post-service, the critical upstream process of securing prior authorization often remains a manual burden. Klivira integrates to automate these pre-service PA workflows, ensuring that claims submitted via your Experian Health Clearinghouse are backed by approved authorizations, minimizing downstream denials and rework.

Key Prior Authorization Triggers in Oncology Workflows

• **J-code chemotherapy and biologic infusions:** Each cycle and regimen change for agents like immunotherapies and targeted therapies typically triggers a PA event.
• **Advanced imaging for staging and surveillance:** High-cost PET/CT, advanced MRI, and tumor-specific molecular imaging for diagnosis and treatment monitoring.
• **Radiation oncology procedures:** IMRT, IGRT, SBRT, brachytherapy, and proton-beam therapy, requiring treatment-plan approval and per-fraction billing PAs.
• **Genetic and molecular testing:** Somatic and germline tumor profiling (NGS panels) for treatment selection and risk stratification.
• **Supportive care medications:** Growth factors (G-CSF, ESAs), antiemetics, and bone-targeting agents, each with dedicated PA pathways.

NCCN Guidelines and Documentation for Oncology PA

The NCCN Clinical Practice Guidelines and NCCN Drugs & Biologics Compendium are the dominant medical-necessity frameworks for oncology prior authorization. Payers commonly require detailed documentation, including pathology reports with histology, AJCC TNM staging, relevant molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), prior-line treatment response, and ECOG/Karnofsky performance status. Klivira's platform is designed with NCCN-compendium-aware policy logic to guide PA coordinators in gathering and submitting this precise documentation, ensuring compliance and accelerating approvals.

Mitigating Common Oncology PA Denials

• **Off-label use without compendium support:** Requests for drugs in indications not supported by NCCN Compendium categories.
• **Step therapy:** Payer requirements for failure or contraindication of less-costly alternatives.
• **Documentation gaps:** Missing pathology subtype, prior-line response duration, or molecular marker results.
• **Site-of-service mismatch:** Infusion requests for facilities not aligned with payer policy.
• **NCD/LCD non-coverage:** Denials for Medicare Advantage plans based on Original Medicare's coverage rules (CMS-NCDs).

Navigating Medical vs. Pharmacy Benefit PAs for Oncology Drugs

Oncology drugs split between medical benefit (provider-administered infusions) and pharmacy benefit (oral oncolytics). This split dictates the PA pathway: medical-benefit PAs route through the payer's medical PA channel, often via X12 278, while pharmacy-benefit PAs route through the payer's PBM and ePA partners. Klivira's system automatically identifies the benefit type and routes the PA through the correct channel, ensuring that the submission aligns with payer requirements, whether it's destined for an X12 278 transaction or an ePA portal like CoverMyMeds or Surescripts.

Klivira's Automation Synergy with Experian Health Clearinghouse

Klivira's platform is designed to complement the robust RCM capabilities of Experian Health Clearinghouse. By automating the entire prior authorization lifecycle—from NCCN-compendium-aware documentation gathering to intelligent routing via X12 278 for medical benefits and ePA partners for pharmacy benefits—Klivira ensures that your oncology claims are primed for efficient processing. This synergy reduces the administrative burden on PA coordinators, accelerates time to treatment, and improves clean claim rates within your Experian Health Clearinghouse framework.